Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
56,260,480
-
Total 13F shares
-
15,442,796
-
Share change
-
+3,995,141
-
Total reported value
-
$714,739,484
-
Price per share
-
$46.30
-
Number of holders
-
82
-
Value change
-
+$184,954,170
-
Number of buys
-
65
-
Number of sells
-
14
Institutional Holders of Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX) as of Q2 2020
As of 30 Jun 2020,
Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX) was held by
82 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
15,442,796 shares.
The largest 10 holders included
EPIQ Capital Group, LLC, Capital Research Global Investors, Capital World Investors, Capital International Investors, SC US (TTGP), LTD., BlackRock Inc., VANGUARD GROUP INC, CITADEL ADVISORS LLC, STATE STREET CORP, and Alphabet Inc..
This page lists
82
institutional shareholders reporting positions in this security
for the Q2 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.